Relief Therapeutics Holding AG (RLF.SW)

CHF 2.41

(2.55%)

Total Liabilities Summary of Relief Therapeutics Holding AG

Relief Therapeutics Holding AG's latest annual total liabilities in 2023 was 24.16 Million CHF , down -44.3% from previous year.
Relief Therapeutics Holding AG's latest quarterly total liabilities in 2024 Q2 was 21.65 Million CHF , down 0.0% from previous quarter.
Relief Therapeutics Holding AG reported annual total liabilities of 43.38 Million CHF in 2022, down -38.1% from previous year.
Relief Therapeutics Holding AG reported annual total liabilities of 70.08 Million CHF in 2021, up 537.05% from previous year.
Relief Therapeutics Holding AG reported quarterly total liabilities of 24.16 Million CHF for 2023 Q4, down 0.0% from previous quarter.
Relief Therapeutics Holding AG reported quarterly total liabilities of 24.16 Million CHF for 2023 FY, down -44.3% from previous quarter.

Annual Total Liabilities Chart of Relief Therapeutics Holding AG (2023 - 2007)

Historical Annual Total Liabilities of Relief Therapeutics Holding AG (2023 - 2007)

Year	Total Liabilities	Total Liabilities Growth
2023	24.16 Million CHF	-44.3%
2022	43.38 Million CHF	-38.1%
2021	70.08 Million CHF	537.05%
2020	11 Million CHF	97.7%
2019	5.56 Million CHF	-61.06%
2018	14.29 Million CHF	42.56%
2017	10.02 Million CHF	9.13%
2016	9.18 Million CHF	-26.36%
2015	12.47 Million CHF	-18.31%
2014	15.27 Million CHF	-39.79%
2013	25.36 Million CHF	538.33%
2012	3.97 Million CHF	41.26%
2011	2.81 Million CHF	-52.54%
2010	5.92 Million CHF	-30.15%
2009	8.48 Million CHF	9.84%
2008	7.72 Million CHF	-47.21%
2007	14.63 Million CHF	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	21.65 Million CHF	0.0%
2023 Q4	24.16 Million CHF	0.0%
2023 FY	24.16 Million CHF	-44.3%
2023 Q2	31.41 Million CHF	0.0%
2022 FY	43.38 Million CHF	-38.1%
2022 Q4	43.38 Million CHF	0.0%
2022 Q2	60.4 Million CHF	0.0%
2021 FY	70.08 Million CHF	537.05%
2021 Q2	55.72 Million CHF	0.0%
2021 Q4	70.08 Million CHF	0.0%
2020 FY	11 Million CHF	97.7%
2020 Q4	11 Million CHF	0.0%
2020 Q2	10.07 Million CHF	0.0%
2019 Q2	10.31 Million CHF	0.0%
2019 FY	5.56 Million CHF	-61.06%
2019 Q4	5.56 Million CHF	0.0%
2018 Q4	14.29 Million CHF	0.0%
2018 Q2	14.32 Million CHF	0.0%
2018 FY	14.29 Million CHF	42.56%
2017 FY	10.02 Million CHF	9.13%
2017 Q4	10.02 Million CHF	0.0%
2017 Q2	9.25 Million CHF	0.0%
2016 Q4	9.18 Million CHF	0.0%
2016 Q2	6.36 Million CHF	0.0%
2016 FY	9.18 Million CHF	-26.36%
2015 Q4	12.47 Million CHF	0.0%
2015 Q2	11.92 Million CHF	0.0%
2015 FY	12.47 Million CHF	-18.31%
2014 Q2	21.91 Million CHF	0.0%
2014 FY	15.27 Million CHF	-39.79%
2014 Q4	15.27 Million CHF	0.0%
2013 FY	25.36 Million CHF	538.33%
2013 Q4	25.36 Million CHF	0.0%
2013 Q2	3.85 Million CHF	0.0%
2012 Q4	3.97 Million CHF	0.0%
2012 FY	3.97 Million CHF	41.26%
2012 Q2	3.03 Million CHF	0.0%
2011 Q2	5.9 Million CHF	0.0%
2011 Q4	2.81 Million CHF	0.0%
2011 FY	2.81 Million CHF	-52.54%
2010 Q2	6.91 Million CHF	0.0%
2010 FY	5.92 Million CHF	-30.15%
2010 Q4	5.92 Million CHF	0.0%
2009 Q4	8.48 Million CHF	0.0%
2009 FY	8.48 Million CHF	9.84%
2009 Q2	11.81 Million CHF	0.0%
2008 FY	7.72 Million CHF	-47.21%
2008 Q4	7.72 Million CHF	0.0%
2007 FY	14.63 Million CHF	0.0%

Peer Total Liabilities Comparison of Relief Therapeutics Holding AG

Name	Total Liabilities	Total Liabilities Difference
Addex Therapeutics Ltd	3.49 Million CHF	-591.05%
BB Biotech AG	304.9 Million CHF	92.075%
Basilea Pharmaceutica AG	183.29 Million CHF	86.818%
Evolva Holding SA	4.27 Million CHF	-465.114%
Idorsia Ltd	1.46 Billion CHF	98.355%
Kuros Biosciences AG	19.19 Million CHF	-25.883%
Molecular Partners AG	21.92 Million CHF	-10.213%
Santhera Pharmaceuticals Holding AG	49.68 Million CHF	51.371%